Morgan Stanley analyst Patrick Wood has maintained their bullish stance on GMED stock, giving a Buy rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Patrick Wood has given his Buy rating due to a combination of factors surrounding Globus Medical’s recent performance and strategic changes. The company reported a slight top-line beat in its pre-announced Q2 results, with organic growth driven partly by contributions from NVRO. This indicates a positive momentum, although some investors expected a larger beat due to competitive pressures in the Spine segment.
Despite the modest beat, the market’s low expectations and the company’s stable guidance for 2025 revenue and EPS suggest a solid foundation. Additionally, the management changes, with Keith Pfeil stepping in as CEO, are seen as a strategic move that could enhance leadership stability. These elements, combined with the anticipation of more detailed insights in the upcoming full report, underpin Wood’s optimistic outlook on the stock.
In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a $105.00 price target.